...
首页> 外文期刊>Radiography >Radiation recall secondary to adjuvant docetaxel after balloon-catheter based accelerated partial breast irradiation
【24h】

Radiation recall secondary to adjuvant docetaxel after balloon-catheter based accelerated partial breast irradiation

机译:基于球囊导管的加速局部乳房照射后,辅助多西他赛继发的放疗

获取原文
获取原文并翻译 | 示例
           

摘要

For early stage breast cancer, wide local excision and post-operative whole breast irradiation is a standard treatment. If adjuvant chemotherapy, is recommended, radiation is usually given after completion of chemotherapy. In recent years, accelerated partial breast irradiation (APBI) with balloon-cathetered based brachytherapy has become an option for selected patients. For these patients, adjuvant chemotherapy would have to be administered after radiation. The sequence of treatment with radiation followed by chemotherapy results in increased risk of radiation recall reaction (RRD) in these patients. Docetaxel is becoming a more commonly used drug as adjuvant treatment for breast cancer. Here we report a case of docetaxel induced RRD after APBI with balloon-cathetered based brachytherapy. Such reaction would have an adverse impact on the cosmetic outcome and quality of life of the patient. For patients who develop an intense skin reaction after the administration of docetaxel following APBI, RRD should be considered in the differential diagnosis.
机译:对于早期乳腺癌,广泛的局部切除术和术后全乳照射是标准治疗方法。如果建议使用辅助化疗,通常在化疗完成后进行放疗。近年来,采用基于球囊导管的近距离放射治疗加速局部乳房照射(APBI)已成为某些患者的选择。对于这些患者,放疗后必须进行辅助化疗。放射治疗后再进行化学治疗的顺序会导致这些患者发生放射回想反应(RRD)的风险增加。多西他赛正成为乳腺癌的辅助治疗药物。在这里,我们报告了一例基于球囊导管的近距离放射治疗在APBI后多西他赛诱导的RRD病例。这样的反应将对患者的美容效果和生活质量产生不利影响。对于在APBI后服用多西他赛后出现强烈皮肤反应的患者,在鉴别诊断中应考虑RRD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号